shutterstock_1843221310_maxshot_pl
MAXSHOT.PL / Shutterstock.com
23 May 2023FeaturesBig PharmaChad Landmon, Ross Blau and Gulrukh Haroon

Effects of GSK v Teva ripple after SCOTUS denies cert

Last week (May 15), the Supreme Court denied certiorari in GlaxoSmithKline v Teva Pharms USA (GSK v Teva), locking in the US Court of Appeals for the Federal Circuit’s second panel decision which held that Teva’s attempted section viii carve-out of an indication covered by a patented method of use was not ‘skinny’ enough to avoid being liable for infringement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Big Pharma
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.
Big Pharma
7 August 2023   GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More on this story

article
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Big Pharma
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.
Big Pharma
7 August 2023   GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More on this story

article
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Big Pharma
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.
Big Pharma
7 August 2023   GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.